Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
4.240
+0.360 (9.28%)
At close: Sep 5, 2025, 4:00 PM
4.200
-0.041 (-0.96%)
After-hours: Sep 5, 2025, 7:53 PM EDT
Voyager Therapeutics Revenue
Voyager Therapeutics had revenue of $5.20M in the quarter ending June 30, 2025, a decrease of -82.42%. This brings the company's revenue in the last twelve months to $42.58M, down -70.38% year-over-year. In the year 2024, Voyager Therapeutics had annual revenue of $80.00M, down -68.00%.
Revenue (ttm)
$42.58M
Revenue Growth
-70.38%
P/S Ratio
5.80
Revenue / Employee
$247,558
Employees
172
Market Cap
235.19M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 80.00M | -170.01M | -68.00% |
Dec 31, 2023 | 250.01M | 209.10M | 511.16% |
Dec 31, 2022 | 40.91M | 3.49M | 9.33% |
Dec 31, 2021 | 37.42M | -133.71M | -78.14% |
Dec 31, 2020 | 171.13M | 66.74M | 63.93% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
VYGR News
- 3 days ago - Voyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 10 days ago - Voyager to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Voyager Reports Second Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 7 weeks ago - Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewsWire
- 3 months ago - Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewsWire
- 4 months ago - Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication - GlobeNewsWire
- 4 months ago - Voyager Reports First Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 4 months ago - Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting - GlobeNewsWire